Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Torsemide vs. Furosemide in Stable Heart Failure
NCT05093621Phase 3Completed
- Sponsor
- Yale University
- Start
- Feb 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of torasemide in heart failure (HF), sponsored by Yale University. Primary endpoint: All-cause Mortality at 1 year. Started Feb 2021; status: completed.
02
Drugs
torasemide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05093621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093621.